SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis (VACOVAJI)

Nantes University Hospital (NUH)

Status: Enrolling

Conditions: SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT05547451

RC22_0237

Details and patient eligibility

About

Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

Enrollment: 200 estimated patients

Sex: All

Ages: 12 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from 12 to 18 years old, on January the 1st 2022
• Patients followed up from juvenile arthritis
• Patients followed up in 2021 and 2022

Exclusion criteria

• Patients under 12 years old.

Trial design

200 participants in 1 patient group

Trial population

Description:

Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.